Patents by Inventor Mary Elizabeth Ewasyshyn

Mary Elizabeth Ewasyshyn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chimeric immunogens
    Patent number: 7244589
    Abstract: Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.
    Type: Grant
    Filed: May 10, 2004
    Date of Patent: July 17, 2007
    Assignee: Sanifo Pasteur Limited
    Inventors: Michel Henri Klein, Run-Pan Du, Mary Elizabeth Ewasyshyn
  • Inactivated respiratory syncytial viral vaccines
    Patent number: 7223410
    Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using ?-propiolactone, a non-ionic detergent, particularly n-octyl-?-D-glucopyranoside and n-octyl-?-D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
    Type: Grant
    Filed: August 5, 1994
    Date of Patent: May 29, 2007
    Assignee: Sanofi Pasteur Limited
    Inventors: Sonia E. Sanhueza, Mary Elizabeth Ewasyshyn, Michel Henri Klein
  • Production of virus and purfication of viral envelope proteins for vaccine use
    Patent number: 6455050
    Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.
    Type: Grant
    Filed: April 26, 1995
    Date of Patent: September 24, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
  • Inactivated respiratory syncytial viral vaccines
    Patent number: 6395469
    Abstract: An immunogenic composition capable of producing a respiratory syncytial (RS) virus specific immune response in a host immunized therewith comprises purified, inactivated RS virus which is substantially free from cellular and serum components and which is non-infectious, non-immunopotentiating, immunogenic and protective. The virus is grown on a vaccine quality cell line and harvested virus is purified under non-denaturing conditions to be substantially free from cellular and serum components. The purified RS virus is inactivated using &bgr;-propiolactone, a non-ionic detergent, particularly n-octyl-&agr;-D-glucopyranoside and n-octyl-&bgr;D-glucopyranoside, or ascorbic acid. The immunogenic composition may be formulated as a vaccine for in vivo administration to a human host. The immunogenic composition also may be used in diagnostic applications.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 28, 2002
    Assignee: Aventis Pasteur Limited
    Inventors: Sonia E. Sanhueza, Mary Elizabeth Ewasyshyn, Michel Henri Klein
  • Production of virus and purification of viral envelope proteins for vaccine use
    Patent number: 6306637
    Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: October 23, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein
  • Production of virus and purification of viral envelope proteins for vaccine use
    Patent number: 6245549
    Abstract: Immunogenic envelope glycoproteins are produced from enveloped virus, such as of the paramyxoviridae family, particularly PIV-3 and RSV, by culturing the virus in the substantial absence of exogenous serum proteins, isolating the virus from the tissue culture, solubilizing the envelope glycoproteins and isolating the solubilized envelope glycoproteins by chromatography.
    Type: Grant
    Filed: November 25, 1991
    Date of Patent: June 12, 2001
    Assignee: Connaught Laboratories Limited
    Inventors: Mary Elizabeth Ewasyshyn, Barry Ian Caplan, Anne-Marie Bonneau, Michel Henri Klein